Louis and Gabi Weisfeld School of Social Work Professor Appointed to European Medicines Agency Advisory Group
Date: 2013-01-17 Hour: 12:32
Prof. Jonathan Rabinowitz, of Bar-Ilan University's Louis and Gabi Weisfeld School of Social Work, has been appointed to the Advisory Group on Promoting Good Analysis Practice in relation to European Medicines Agency (EMA) Clinical Trial Data and Transparency, which is set up to inform the upcoming EMA policy on clinical trial data transparency. In addition he has been appointed Co-Chair of the Program Committee for the Biennial Schizophrenia International Research Society Conference to take place in Florence, Italy, April 5-9, 2014.
Prof. Rabinowitz is a pioneer in the field of data sharing. His work is part of an international consortium called NEWMEDS (an acronym for Novel Methods leading to NeW MEdications in Depression and Schizophrenia). As part of the project, Rabinowitz has been given unprecedented access to data on drug testing from over 35,000 patients in over 100 trials of antipsychotic and antidepressant compounds spanning 25 countries. NewMeds is funded by the Innovative Medicines Initiative Joint Undertaking, a public-private partnership between the pharmaceutical industry (represented by the European Federation of Pharmaceutical Industries and Associations) and the European Union.